This study examined the effects of 28-d treatment with vildagliptin ( 100 mg , twice daily ; n = 9 ) vs. placebo ( n = 11 ) on beta-cell function in diabetic patients using a mathematical model that describes the insulin secretory rate as a function of glucose levels ( beta-cell dose response ) , the change in glucose with time ( derivative component ) , and a potentiation factor , which is a function of time and may reflect the actions of nonglucose secretagogues and other factors .
